Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

ere were 4 SAEs in 3 subjects (2 embolism, toe gangrene, pain in thigh).

All SAEs out of all studies using AMG0001 were evaluated by the DSMB (Data Safety Monitoring Board) and it was concluded that, as of today, there is no major safety concern related to AMG0001.

While significant improvement was confirmed based on the efficacy evaluation, as AMG0001 is a highly novel therapeutic, AnGes will continue development by carefully following the safety.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

About AnGes MG

AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on innovative discoveries by researchers of Osaka University. The company specializes in research and development and practical application of DNA-based therapeutics. The company, along with its subsidiaries, is engaged in developing three new medicines: HGF genetic medicine which improves blood circulation by regeneratin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... , LAKE FOREST, Ill. , ... and manufacturer of injectable pharmaceuticals, announced today the acquisition ... number of products in development from GeneraMedix Inc. , ... additions to our portfolio, which demonstrates our continuing commitment ...
... , KINGWOOD, Texas , Feb. 12 ... that the company has formally offered to purchase an equity ... in the chronic pain management medical sector. The pharmaceutical company ... identified until IMAI has a signed letter of intent from ...
Cached Medicine Technology:Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc. 2International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain 2
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2
... Drug Trend for 2008-- Drug Trend managed to a ... than 40 percent mail order experienced a negative drug ... inflation hit its highest level in five years, but ... growth to 3.3 percent, a new report released by ...
... of hereditary hemochromatosis , is frequently found in ... non-alcoholic fatty liver disease patients . A study ... and steatosis in a non-obese cohort of non-alcoholic ... after exclusion of diagnosis of HH, represent a ...
... (NPR-B) gene was expressed in gastric smooth muscles ... was increased in diabetic rats. These results suggest ... it may contribute to diabetic gastroparesis in STZ-induced ... is frequent in diabetic patients. It is a ...
... Mango, the very popular and fastest-growing retailer of authentic ... "AKA" seal, a certification confirming that Red Mango,s frozen ... high quality, delicious treat by nationally recognized Celebrity Dietitian ... and nutritionist in Los Angeles by Citysearch.com for the ...
... Caron Treatment Centers Poll Examines Challenges , Women ... EmpowermentPHILADELPHIA, May 13 From decreased intimacy ... is having a profound impact on relationships, according to ... Centers , one of the nation,s leading non-profit ...
... CareFusion Corporation, the company that will become public ... medical products businesses, today announced that Edward J. Borkowski ... has been CFO of Mylan, Inc. since 2002 where ... business to one of the largest generic pharmaceutical companies ...
Cached Medicine News:Health News:Mail Service and Higher Generic Use Helps Keep Spending in Check, Countering Brand Drug Price Inflation and Specialty Medication Growth 2Health News:Mail Service and Higher Generic Use Helps Keep Spending in Check, Countering Brand Drug Price Inflation and Specialty Medication Growth 3Health News:Mail Service and Higher Generic Use Helps Keep Spending in Check, Countering Brand Drug Price Inflation and Specialty Medication Growth 4Health News:Mail Service and Higher Generic Use Helps Keep Spending in Check, Countering Brand Drug Price Inflation and Specialty Medication Growth 5Health News:NPs-NPR-B/pGC-cGMP signal pathway is involved in diabetic gastroparesis 2Health News:Red Mango Receives 'AKA' Stamp of Approval From Ashley Koff, R.D., Underscoring Its Commitment to Good Health 2Health News:Red Mango Receives 'AKA' Stamp of Approval From Ashley Koff, R.D., Underscoring Its Commitment to Good Health 3Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 2Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 3Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 4Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 5Health News:CareFusion Names Edward Borkowski as Chief Financial Officer 2Health News:CareFusion Names Edward Borkowski as Chief Financial Officer 3Health News:CareFusion Names Edward Borkowski as Chief Financial Officer 4
The combination of new measuring principle - Pupil Zone Imaging Method - and unique technology - SLD - offers high accuracy and reliability in refraction measurement....
... Module ACM-8 loads and unloads two centrifuges ... Identification via Cap Recognition the tube type ... in batches of three 5 position racks ... the single centrifuge ACM can be offered ...
... The Recapping System RCS 800 closes various ... efficient and easy way. Different tube heights and ... sealed tubes can be used for send-outs. The ... RSD 800, Aliquoting System RSD 800 and High ...
... detect sequences of the following viruses: ... and 3; influenza virus A and ... and B. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
Medicine Products: